Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced the results of its special meeting of shareholders (“special meeting”) held...
Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has released...
Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured...
Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy, recently announced a definitive agreement to combine with the advanced AI company GEDiCube...
Renovaro BioSciences (NASDAQ: RENB), an advanced, preclinical biotechnology company, and GEDi Cube Intl Ltd., an AI medical technology company, previously announced a definitive agreement to combine. The...
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.
In September, Renovaro Biosciences (NASDAQ: RENB), an advanced, preclinical biotechnology company focused on cell, gene, and immunotherapy, and GEDiCube Intl Ltd., an AI medical technology company, announced...
Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell and immunotherapy platforms that modulate immune responses against cancers and...
Renovaro Biosciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors with short life expectancy, recently announced a definitive agreement...
Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell, and immunotherapy platforms that modulate immune responses against cancers and...